GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » Free Cash Flow per Share

IRIDEX (IRIDEX) Free Cash Flow per Share

: $-0.43 (TTM As of Dec. 2023)
View and export this data going back to 1996. Start your Free Trial

IRIDEX's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.06. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.43.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -20.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the FCF Growth Rate using Free Cash Flow per Share data.

The historical rank and industry rank for IRIDEX's Free Cash Flow per Share or its related term are showing as below:

IRIX' s 3-Year FCF Growth Rate Range Over the Past 10 Years
Min: -80.9   Med: -7.95   Max: 29.5
Current: -20.8

During the past 13 years, IRIDEX's highest 3-Year average Free Cash Flow per Share Growth Rate was 29.50% per year. The lowest was -80.90% per year. And the median was -7.95% per year.

IRIX's 3-Year FCF Growth Rate is ranked worse than
72.83% of 622 companies
in the Medical Devices & Instruments industry
Industry Median: 0.5 vs IRIX: -20.80

IRIDEX Free Cash Flow per Share Historical Data

The historical data trend for IRIDEX's Free Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Free Cash Flow per Share
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.59 -0.24 0.52 -0.62 -0.43

IRIDEX Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Free Cash Flow per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.11 -0.18 -0.07 -0.12 -0.06

Competitive Comparison

For the Medical Devices subindustry, IRIDEX's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRIDEX Price-to-Free-Cash-Flow Distribution

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where IRIDEX's Price-to-Free-Cash-Flow falls into.



IRIDEX Free Cash Flow per Share Calculation

Free Cashflow per Share is the amount of Free Cashflow per outstanding share of the company's stock.

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Note: GuruFocus does not calculate Free Cash Flow Per Share when Capital Expenditure is 0.

IRIDEX's Free Cash Flow Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Free Cash Flow Per Share(A: Dec. 2023 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(-6.745+-0.109)/16.128
=-6.854/16.128
=-0.42

IRIDEX's Free Cash Flow Per Share for the quarter that ended in Dec. 2023 is calculated as

Free Cash Flow Per Share(Q: Dec. 2023 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(-0.979+0.032)/16.245
=-0.947/16.245
=-0.06

Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IRIDEX  (NAS:IRIX) Free Cash Flow per Share Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Dec23, IRIDEX's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Dec23)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0.10609524/2.81+-0.103
=-6.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


IRIDEX Free Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of IRIDEX's Free Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


IRIDEX (IRIDEX) Business Description

Traded in Other Exchanges
N/A
Address
1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Executives
Nandini Devi director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss director C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp 10 percent owner 75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp 10 percent owner 111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous director C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda director 402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer officer: COO 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne director
Robert A Gunst director
David Bruce director, officer: President and CEO 1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum director
Romeo R Dizon other: Vice President and Controller 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043

IRIDEX (IRIDEX) Headlines

From GuruFocus

Iridex to Present at the 34th Annual Roth Conference

By GuruFocusNews GuruFocusNews 03-08-2022

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 05-12-2022

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 07-01-2022

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 06-21-2022

Iridex Announces First Quarter 2022 Financial Results

By PurpleRose PurpleRose 07-11-2022